ABBV vs PFE
AbbVie Inc. and Pfizer Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | ABBV | PFE |
|---|---|---|
| Revenue | $61.2B | $62.6B |
| Net income | $4.2B | $7.8B |
| Gross margin | 70.2% | 74.3% |
| Net margin | 6.9% | 12.4% |
| Return on equity | 15367.3% | 8.9% |
| Diluted EPS | $2.36 | $1.36 |
| Dividend / share | $6.65 | $1.72 |
| Payout ratio | 275.8% | — |
| Free cash flow | $17.8B | $9.1B |
| Equity | $-3.3B | $86.5B |
| Net debt / equity | 16.49× | 0.73× |
| Current ratio | 0.67× | 1.16× |
| Revenue CAGR 5y | 6.0% | 8.5% |
| Profit CAGR 5y | −1.7% | −3.2% |
ABBV and PFE book revenue within 15% of each other, and PFE keeps more of each dollar of revenue as profit (12.4% against 6.9%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | ABBV | PFE |
|---|---|---|
| FY2025 | $61.2B | $62.6B |
| FY2024 | $56.3B | $63.6B |
| FY2023 | $54.3B | $59.6B |
| FY2022 | $58.1B | $101.2B |
| FY2021 | $56.2B | $73.6B |
| FY2020 | $45.8B | $41.7B |
| FY2019 | $33.3B | $40.9B |
| FY2018 | $32.8B | $40.8B |
| FY2017 | $28.2B | $52.5B |
| FY2016 | $25.6B | $52.8B |
Net income by year
Bottom line
| Fiscal year | ABBV | PFE |
|---|---|---|
| FY2025 | $4.2B | $7.8B |
| FY2024 | $4.3B | $8.0B |
| FY2023 | $4.9B | $2.1B |
| FY2022 | $11.8B | $31.4B |
| FY2021 | $11.5B | $22.0B |
| FY2020 | $4.6B | $9.2B |
| FY2019 | $7.9B | $16.0B |
| FY2018 | $5.7B | $11.2B |
| FY2017 | $5.3B | $21.3B |
| FY2016 | $6.0B | $7.2B |
Advertisement
AdSense · Rectangle 336×280